Successful treatment of refractory anterior scleritis in primary Sjögren's syndrome with rituximab

Annals of the Rheumatic Diseases

Volumn 64, Issue 7, 2005, Pages 1087-1088

  Ahmadi Simab, K ^a   Lamprecht, P ^a   Nolle B ^b   Ai, M ^a   Gross, W L ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID;

ADULT; ARTHRALGIA; ARTICLE; B LYMPHOCYTE; CASE REPORT; EPISCLERITIS; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; REMISSION; SCLERITIS; SJOEGREN SYNDROME; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; SCLERITIS; SJOGREN'S SYNDROME;

EID: 21344471920     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.027128     Document Type: Article

References (10)

1. Fox RI, Stern M, Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol 2000;12:391-8.
2. Sainz de la Maza M, Jabbur NS, Foster CS. Severity of scleritis and episcleritis. Ophthalmology 1994;101:389-96.
3. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European community. Arthritis Rheum 1993;36:340-7.
4. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900-8.
5. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-1932.
6. Leonardo MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erthemathosus. Arthritis Rheum 2002;46:2673-7.
7. Levine TD. A pilot study of rituximab therapy for refractory dermatomyositis [abstract]. Arthritis Rheum 2002;46(suppl):S488.
8. Lamprecht P, Lerin-Lozano C, Merz H, Dennin RH, Gause A, Voswinkel J, et al. Rituximab induces remission in refractory HCV-associated cryoglobulinemic vasculitis. Ann Rheum Dis 2003;62:1230-3.
9. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146-54.
10. Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, Scholze J, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2002;46:2160-71.